Evaluation of analgesia duration of Botulinum Toxin-A in chronic orafacial pain

Objective: Botulinum Toxin-A is a strong biological toxin synthesized by Clostridium botulinum which is a gram positive, anaerobic, spore forming organism. Its mechanism of inhibiting acetylcholine release at neuromuscular junctions following local injection is unique. Other dose-dependent anti-neuroinflammatory effects and vascular modulating properties have extended its spectrum of applications. Recurrent applications may be required because of its time limited paralysing effect. However duration of analgesic affect of Botulinum Toxin-A in chronic pain is still controversial. The aim of this report is to evaluate anelgesia duration of Botulinum Toxin-A in chronic orafacial pain patients .

Patients and methods: 15 patients with a complaint of chronic orofacial pain were included in the study. Pre and post operative symptoms were recorded. After Botulinum Toxin-A injection, pain was evaluated with Visual Analog Scale at 1st, 3rd, 7th day, 1 month and 6 month. Their long term (mean 18 months) follow-up values were also evaluated.

Results: At the end of mean 18 months follow up period 80% of the patients’ pain values were significantly decreased following Btx-A application, only 20% of the patients have similar pain values and symptoms as initial. In long term (18 months) follow-up mean pain values were decreased from 6.65 to 2.5.

Conclusion: Botulinum Toxin-A is an effective analgesic drug in chronic orofacial pain.

Conflict of interest: None declared.

Only gold members can continue reading. Log In or Register to continue

Feb 5, 2018 | Posted by in Oral and Maxillofacial Surgery | Comments Off on Evaluation of analgesia duration of Botulinum Toxin-A in chronic orafacial pain
Premium Wordpress Themes by UFO Themes